Email updates

Keep up to date with the latest news and content from BMC Infectious Diseases and BioMed Central.

Open Access Technical advance

An update of “Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model”

Hong Anh T Tu*, Mark H Rozenbaum, Pieter T de Boer, Albert C Noort and Maarten J Postma

Author Affiliations

Institute of Health Policy, Management and Evaluation, University of Toronto, Ontario, Canada

For all author emails, please log on.

BMC Infectious Diseases 2013, 13:54  doi:10.1186/1471-2334-13-54

Published: 30 January 2013

Abstract

Background

To update a cost-effectiveness analysis of rotavirus vaccination in the Netherlands previously published in 2011.

Methods

The rotavirus burden of disease and the indirect protection of older children and young adults (herd protection) were updated.

Results

When updated data was used, routine infant rotavirus vaccination in the Netherlands would potentially become an even more cost-effective strategy than previously estimated with the incremental cost per QALY at only €3,000-4,000. Break-even total vaccination costs were indicated at €92–122, depending on the applied threshold.

Conclusions

We concluded that the results on potentially favourable cost-effectiveness in the previous study remained valid, however, the new data suggested that previous results might represent an underestimation of the economic attractiveness of rotavirus vaccination.

Keywords:
Cost-effectiveness analysis; Rotavirus vaccination; the Netherlands